In a phase 2 trial, the combination of alisertib and paclitaxel as a second-line treatment demonstrated superior PFS benefits for patients with relapsed SCLC expressing MYC compared to monotherapy with paclitaxel (PFS 4.6 months vs. 2.3 months; HR = 0.29, 95% CI 0.12–0.72) [158]. The gene discussed is MYC; the disease is small cell lung carcinoma.